Valuing Biotech Companies

Valuations depend on forecasts. The reliability of the forecasts will then depend heavily on complete analysis of the industry, in addition to the evolving changes in the economy. It also requires understanding of the business and financial characteristic of the industry.

Biotech companies’ values are primarily driven by intellectual property, they do not need to rely much on their suppliers. These companies also have relatively easy access to sources of raw materials (such as chemicals), scientific tools, computers and testing equipment.

Page 3 Page 7 Page 12 Page 17 Page 20 Positive Accounting Theory Ethics in Accounting Accounting for Physical Assets & Intangible Assets Accounting for Assets in Mining & Agricultural Industries ounting Accounting for Provisions

E. Cindy and Rob estimate that the market value of the common equity in the venture is $900,000 at the end of 2010. The market values of interest-bearing debt are judged to be the same as the recorded book values at the end of 2010. Estimate the market value-based weighted average cost of capital for Castillo Products.

Improvements in health care and life sciences are an important source of gains in health and longevity globally. The development of innovative pharmaceutical products plays a critical role in ensuring these continued gains. To encourage the continued development of new drugs, economic incentives are essential. These incentives are principally provided through direct and indirect government funding, intellectual property laws, and other policies that favor innovation. Without such incentives, private corporations, which bring to market the vast majority of new drugs, would be less able to assume the risks and costs necessary to continue their research and development (R&D). In the United States, government action has focused on creating the environment that would best encourage further innovation and yield a constant flow of new and innovative medicines to the market. The goal has been to ensure that consumers would benefit both from technological breakthroughs and the competition that further innovation generates. The United States also relies on a strong generic pharmaceutical industry to create added competitive pressure to lower drug prices. Recent action by the Administration and Congress has accelerated the flow of generic medicines to the market for precisely that reason. By contrast, in the Organization for Economic Cooperation and

The most obvious reason for the difference between the market value of equity and the book value of equity is the inability to record certain intangible assets such as brand value, customer loyalty, and perhaps most importantly, human capital. These intangible assets are likely to provide tremendous earnings growth in the future which determines the company’s market value. Notice also that the company’s choice of conservative accounting policies has the effect of depressing the company’s book value of equity.

Proponents of patent reform largely focus on the cost of patent infringement litigation to the U.S. economy and companies. While some argue that the type of patents issued should be limited in order to uphold the intent of Article I, Section 8, others claim that standards for issuing patents should be strengthened in order to reduce the number of costly patent infringement lawsuits. The cost of litigation and standards for issuing a patent is the focus of the proceeding text and justification for patent reform in the United States.

The topic of valuation of early-stage companies, patents, and technologies have been a topic of study since the late 1980’s. Since the work published by Amit et al (1990) a body of management science literature was published around the value relevance of non-financial information that quantifies the human capital of the founding team. Amit et al posit that

This case discusses Cross-Border valuation of projects. This kind of analysis is common for companies that are operating in many countries. Groupe Ariel is one such company that is considering investing in a project in its own subsidiary in Mexico. The company manufactures and sells printers, copiers and other document production equipment in many countries. As far as, expansion into new markets is concerned, company is very slow in taking initiatives as compared to its competitors owing to the recent recession. But the management of the company believes that better durability and lower after-sales service costs of their products enable

The biggest change in Abbott’s balance sheet can be seen in the composition of its asset accounts. In 2006, % of the firm’s assets were current, while 69% were of the long-term variety. In 2010, however, the portion of current assets increased by 7%. This increase in current assets is most visible in cash and short-term investments (4% in 2006 to 9% in 2010) and corresponds with a higher level of uncertainty in today’s economy. The fact that Abbott Laboratories has chosen to increase the value of liquid assets on its balance sheet indicates low returns on long-term investments and a preference of keeping cash on hand rather than reinvesting in the business.

This week examines developments from biotech companies AstraZeneca (AZN), Relypsa (RLYP), and Mast Therapeutics (MSTX) where recent FDA and management announcements have the potential to significantly impact the stock’s potential. In both scenarios below, speaking to an expert will help investors gain insights into these complex situations and perform fundamental diligence.

We valued the company using four different methods; Net Present Value, Internal Rate of Return, Modified Internal Rate of Return and Profitability Index. We began with the Net Present Value, or NPV, calculation. NPV values an investment’s profitability based on the projected future cash inflows and outflows of the investment, discounted back to present value using the WACC. The calculations for NPV are presented in Appendix 2. We started by separating cash inflows and outflows by each year. We used Bob Prescott’s estimates for the revenue per year and related operating costs of cost of goods sold as

Most biotechnology companies have their unique products. For example, the CSL's specialty is Vaccines & Plasma Products and COH is specializing in the Cochlear Implant Systems. Once the drug is discovered or invented, it is hard for other competitors to imitate because majority drug companies used the patent system. (thusleem,2008). Thus,there is less competititive in the market.

McGahan, A. M., & Silverman, B. S. (2006). Profiting from technological innovation by others: The effect of competitor patenting on firm value. Research Policy, 35(8), 1222-1242.

Other, more current businesses have gotten to be similarly or much more reliant on protected innovation rights. The designers and wholesalers of machine programming, for instance, demand that their capacity to stay in business is reliant on their energy to keep the unapproved propagation of their manifestations. Protected innovation assurance is broadly thought to be significantly more paramount to the quickly developing biotechnology industry, where the advancement of new systems of hereditary designing or of new life-structures utilizing such methods can be amazingly lavish. Biotechnology firms contend that, in the event that they were not able to keep rivals from mirroring their manifestations, they would not have the capacity to recover their expenses and hence would have no motivator to put resources into the innovative work fundamental for experimental leaps forward. Organizations offering merchandise and administrations over the Internet have made comparable cases concerning the significance of their space names.